There are 2789 resources available
1133P - Whole genome sequencing can classify diagnostically challenging tumors
Presenter: Luuk Schipper
Session: ePoster Display
1188P - Concurrent chemoradiotherapy with cisplatin + S-1 for locally advanced non-small cell lung cancer: IPD meta-analysis
Presenter: Yuri Taniguchi
Session: ePoster Display
1189P - EGFR mutation p.747_749del enhances anlotinib sensitivity by upregulating EGR1 and DUSP6 in NSCLC cells
Presenter: yu limeng
Session: ePoster Display
1190TiP - SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
Presenter: Rafal Dziadziuszko
Session: ePoster Display
1195P - Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
Presenter: Sanjay Popat
Session: ePoster Display
1298P - PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
Presenter: Sally Lau
Session: ePoster Display
1299P - Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Presenter: Konstantinos Rounis
Session: ePoster Display
1302P - Immune signatures of second-line PD-1 immune checkpoint blockade
Presenter: Kenneth O'Byrne
Session: ePoster Display
1303P - A clinical variable based nomogram could predict survival for NSCLC patients receiving atezolizumab
Presenter: Xiaoling Shang
Session: ePoster Display
1304P - Interleukin-6 (IL-6) as a potential predictive marker and a desensitizer for immunotherapy response in non-small cell lung cancer
Presenter: Yan Wang
Session: ePoster Display